BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 22640662)

  • 1. Concurrent radiochemotherapy in locally-regionally advanced oropharyngeal squamous cell carcinoma: analysis of treatment results and prognostic factors.
    Krstevska V; Stojkovski I; Zafirova-Ivanovska B
    Radiat Oncol; 2012 May; 7():78. PubMed ID: 22640662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cisplatin superior to carboplatin in adjuvant radiochemotherapy for locally advanced cancers of the oropharynx and oral cavity.
    Rades D; Ulbricht T; Hakim SG; Schild SE
    Strahlenther Onkol; 2012 Jan; 188(1):42-8. PubMed ID: 22194029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concurrent cisplatin and radiation versus cetuximab and radiation for locally advanced head-and-neck cancer.
    Koutcher L; Sherman E; Fury M; Wolden S; Zhang Z; Mo Q; Stewart L; Schupak K; Gelblum D; Wong R; Kraus D; Shah J; Zelefsky M; Pfister D; Lee N
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):915-22. PubMed ID: 20947269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prognostic factors for locally advanced cervical cancer patients treated by intensity-modulated radiation therapy with concurrent chemotherapy.
    Chen CC; Wang L; Lin JC; Jan JS
    J Formos Med Assoc; 2015 Mar; 114(3):231-7. PubMed ID: 25777974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concurrent radiochemotherapy in advanced hypopharyngeal cancer.
    Krstevska V; Stojkovski I; Lukarski D
    Radiat Oncol; 2010 May; 5():39. PubMed ID: 20482772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II/III Randomized Controlled Trial of Concomitant Hyperfractionated Radiotherapy plus Cetuximab (Anti-EGFR Antibody) or Chemotherapy in Locally Advanced Head and Neck Cancer.
    Al-Saleh K; El-Sherify M; Safwat R; Elbasmy A; Shete J; Hussein A; Nazeeh M; Bedair A
    Gulf J Oncolog; 2019 May; 1(30):6-12. PubMed ID: 31242976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of chemotherapy regimen on treatment outcomes in patients with HPV-associated oropharyngeal cancer with T4 disease treated with definitive concurrent chemoradiation.
    Bhattasali O; Ryoo JJ; Thompson LDR; Abdalla IA; Chen J; Iganej S
    Oral Oncol; 2019 Aug; 95():74-78. PubMed ID: 31345397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of intensity-modulated radiation therapy and concomitant boost radiotherapy in the setting of concurrent chemotherapy for locally advanced oropharyngeal carcinoma.
    Lee NY; de Arruda FF; Puri DR; Wolden SL; Narayana A; Mechalakos J; Venkatraman ES; Kraus D; Shaha A; Shah JP; Pfister DG; Zelefsky MJ
    Int J Radiat Oncol Biol Phys; 2006 Nov; 66(4):966-74. PubMed ID: 17145527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant chemotherapy followed by concurrent hyperfractionated radiation therapy and sensitizing chemotherapy for locally advanced (T3-T4) oropharyngeal squamous cell carcinoma.
    Finnegan V; Parsons JT; Greene BD; Sharma V
    Head Neck; 2009 Feb; 31(2):167-74. PubMed ID: 18853443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [SIB-IMRT radiotherapy given concomitantly with cisplatin for locally advanced squamous cell head and neck cancer (SCHNC). Evaluation of the early results and toxicity].
    Kiprian D; Jarząbski A; Pawłowska B; Michalski W; Kawecki A
    Otolaryngol Pol; 2011 Sep; 65(5 Suppl):117-25. PubMed ID: 22000261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyperfractionated accelerated radiotherapy in combination with weekly cisplatin for locally advanced head and neck cancer.
    Beckmann GK; Hoppe F; Pfreundner L; Flentje MP
    Head Neck; 2005 Jan; 27(1):36-43. PubMed ID: 15459918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patterns of Treatment Failure and Postrecurrence Outcomes Among Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma After Chemoradiotherapy Using Modern Radiation Techniques.
    Leeman JE; Li JG; Pei X; Venigalla P; Zumsteg ZS; Katsoulakis E; Lupovitch E; McBride SM; Tsai CJ; Boyle JO; Roman BR; Morris LGT; Dunn LA; Sherman EJ; Lee NY; Riaz N
    JAMA Oncol; 2017 Nov; 3(11):1487-1494. PubMed ID: 28542679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concomitant low-dose cisplatin and three-dimensional conformal radiotherapy for locally advanced squamous cell carcinoma of the head and neck: Analysis of survival and toxicity.
    Lau H; Brar S; Hao D; MacKinnon J; Yee D; Gluck S
    Head Neck; 2006 Mar; 28(3):189-96. PubMed ID: 16265658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized phase III study of 2 cisplatin-based chemoradiation regimens in locally advanced head and neck squamous cell carcinoma: impact of changing disease epidemiology on contemporary trial design.
    Rodriguez CP; Adelstein DJ; Rybicki LA; Savvides P; Saxton JP; Koyfman SA; Greskovich JF; Yao M; Scharpf J; Lavertu P; Wood BG; Burkey BB; Lorenz RR; Rezaee RP; Zender CA; Ives DI
    Head Neck; 2015 Nov; 37(11):1583-9. PubMed ID: 24909549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 2 study of docetaxel, cisplatin, and concurrent radiation for technically resectable stage III-IV squamous cell carcinoma of the head and neck.
    Inohara H; Takenaka Y; Yoshii T; Nakahara S; Yamamoto Y; Tomiyama Y; Seo Y; Isohashi F; Suzuki O; Yoshioka Y; Sumida I; Ogawa K
    Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):934-41. PubMed ID: 25832686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of concurrent carboplatin plus radiotherapy for locally advanced head and neck cancer patients ineligible for treatment with cisplatin.
    Hamauchi S; Yokota T; Onozawa Y; Ogawa H; Onoe T; Kamijo T; Iida Y; Nishimura T; Onitsuka T; Yasui H
    Jpn J Clin Oncol; 2015 Dec; 45(12):1116-21. PubMed ID: 26423341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial.
    Rischin D; Young RJ; Fisher R; Fox SB; Le QT; Peters LJ; Solomon B; Choi J; O'Sullivan B; Kenny LM; McArthur GA
    J Clin Oncol; 2010 Sep; 28(27):4142-8. PubMed ID: 20697079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of cisplatin dose intensity on human papillomavirus-related and -unrelated locally advanced head and neck squamous cell carcinoma.
    Spreafico A; Huang SH; Xu W; Granata R; Liu CS; Waldron JN; Chen E; Ringash J; Bayley A; Chan KK; Hope AJ; Cho J; Razak AA; Hansen A; Jang R; Perez-Ordonez B; Weinreb I; Bossi P; Orlandi E; Licitra LF; Song Y; O'Sullivan B; Siu LL; Kim J
    Eur J Cancer; 2016 Nov; 67():174-182. PubMed ID: 27669504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Locally advanced head and neck cancer treated with accelerated radiotherapy, the hypoxic modifier nimorazole and weekly cisplatin. Results from the DAHANCA 18 phase II study.
    Bentzen J; Toustrup K; Eriksen JG; Primdahl H; Andersen LJ; Overgaard J
    Acta Oncol; 2015 Jul; 54(7):1001-7. PubMed ID: 25629651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of human papillomavirus in oropharyngeal squamous cell carcinomas.
    Sedaghat AR; Zhang Z; Begum S; Palermo R; Best S; Ulmer KM; Levine M; Zinreich E; Messing BP; Gold D; Wu AA; Niparko KJ; Kowalski J; Hirata RM; Saunders JR; Westra WH; Pai SI
    Laryngoscope; 2009 Aug; 119(8):1542-9. PubMed ID: 19522004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.